CN115361960A - 用于治疗慢性移植物抗宿主病的方法 - Google Patents

用于治疗慢性移植物抗宿主病的方法 Download PDF

Info

Publication number
CN115361960A
CN115361960A CN202180027192.3A CN202180027192A CN115361960A CN 115361960 A CN115361960 A CN 115361960A CN 202180027192 A CN202180027192 A CN 202180027192A CN 115361960 A CN115361960 A CN 115361960A
Authority
CN
China
Prior art keywords
cells
score
point
stem cells
mesenchymal lineage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180027192.3A
Other languages
English (en)
Chinese (zh)
Inventor
S·伊茨库
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mesoblast International SARL
Original Assignee
Mesoblast International SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020900472A external-priority patent/AU2020900472A0/en
Application filed by Mesoblast International SARL filed Critical Mesoblast International SARL
Publication of CN115361960A publication Critical patent/CN115361960A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0669—Bone marrow stromal cells; Whole bone marrow

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180027192.3A 2020-02-19 2021-02-18 用于治疗慢性移植物抗宿主病的方法 Pending CN115361960A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020900472 2020-02-19
AU2020900472A AU2020900472A0 (en) 2020-02-19 Method for treating chronic graft versus host disease
PCT/EP2021/054066 WO2021165420A1 (en) 2020-02-19 2021-02-18 Method for treating chronic graft versus host disease

Publications (1)

Publication Number Publication Date
CN115361960A true CN115361960A (zh) 2022-11-18

Family

ID=74701467

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180027192.3A Pending CN115361960A (zh) 2020-02-19 2021-02-18 用于治疗慢性移植物抗宿主病的方法

Country Status (9)

Country Link
US (1) US20230097931A1 (https=)
EP (1) EP4106776A1 (https=)
JP (1) JP2023513847A (https=)
KR (1) KR20220143092A (https=)
CN (1) CN115361960A (https=)
AU (1) AU2021222342A1 (https=)
BR (1) BR112022016448A2 (https=)
CA (1) CA3168330A1 (https=)
WO (1) WO2021165420A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070258963A1 (en) 2006-01-13 2007-11-08 Osiris Therapeutics, Inc. Mesenchymal stem cells expressing TNF-alpha receptors
US20120087868A1 (en) 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
SG11202004680UA (en) 2017-11-22 2020-06-29 Mesoblast Int Sarl Cellular compositions and methods of treatment i
WO2024168161A1 (en) * 2023-02-08 2024-08-15 Mesoblast International Sarl Potency assay and manufacturing method

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080292600A1 (en) * 2005-06-17 2008-11-27 Song Sun Uk Treatment of graft-versus-host disease
US20150307844A1 (en) * 2013-11-04 2015-10-29 Isopogen Pty Ltd Cell culture method
CN110753751A (zh) * 2017-05-04 2020-02-04 迈索布拉斯特国际有限公司 具有增强的免疫抑制的间充质谱系前体或干细胞

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6251295B1 (en) 1998-01-08 2001-06-26 Nexell Therapeutics Inc. Method for recirculation washing of blood cells
EP1795588A1 (en) * 2005-12-07 2007-06-13 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
EP2324109B1 (en) * 2008-09-03 2016-10-26 Mesoblast, Inc. Expansion of haemopoietic precursors
US20120087868A1 (en) * 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080292600A1 (en) * 2005-06-17 2008-11-27 Song Sun Uk Treatment of graft-versus-host disease
CN101754767A (zh) * 2007-05-25 2010-06-23 同种疗法有限公司 移植物抗宿主疾病的治疗
US20150307844A1 (en) * 2013-11-04 2015-10-29 Isopogen Pty Ltd Cell culture method
CN105765059A (zh) * 2013-11-04 2016-07-13 伊索波根控股公司 细胞培养方法
CN110753751A (zh) * 2017-05-04 2020-02-04 迈索布拉斯特国际有限公司 具有增强的免疫抑制的间充质谱系前体或干细胞

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ZHOU HONG等: "Efficacy of Bone Marrow-Derived Mesenchymal Stem Cells in the Treatment of Sclerodermatous Chronic Graft-Versus - Host Disease Clinical Report", BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, vol. 16, no. 3, 1 March 2010 (2010-03-01), pages 403 - 412, XP055802500, DOI: 10.1016/j.bbmt.2009.11.006 *
周虹等: "骨髓间充质干细胞移植治疗硬皮病样慢性移植物抗宿主病:4例免疫机制变化", 中国组织工程研究与临床康复, no. 10, 5 March 2010 (2010-03-05), pages 187 - 193 *
杨晶等: "慢性移植物抗宿主病的发病机制及治疗进展", 中南大学学报(医学版), no. 05, 15 May 2019 (2019-05-15), pages 117 - 125 *

Also Published As

Publication number Publication date
JP2023513847A (ja) 2023-04-03
BR112022016448A2 (pt) 2022-11-29
AU2021222342A1 (en) 2022-09-15
US20230097931A1 (en) 2023-03-30
EP4106776A1 (en) 2022-12-28
WO2021165420A1 (en) 2021-08-26
KR20220143092A (ko) 2022-10-24
CA3168330A1 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
US10358629B2 (en) Regulating stem cells
CN115361960A (zh) 用于治疗慢性移植物抗宿主病的方法
CN115361959A (zh) 用于使用间充质谱系前体或干细胞治疗过度炎症的方法
KR20220152240A (ko) 염증성 장 질환 ii의 치료 방법
US20230172991A1 (en) Method for treating inflammatory bowel disease i
US20230293589A1 (en) Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells
US20240197787A1 (en) Method for treating acute respiratory distress syndrome (ards) in specific patients using mesenchymal lineage precursor or stem cells
US20250032552A1 (en) Method of treating severe graft versus host disease
JP2025521740A (ja) 凍結保存中間体及びそれに対する効力アッセイ
AU2024332651A1 (en) Third line treatment for gvhd
IL193947A (en) Cells cultured as cd31brigi: it, a method for stimuli to differentiate into a congenital / precursor cell population (pcp), use of the same drug preparation population, and implantation device that includes it

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination